Trial Profile

An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATYR 1940 (Primary)
Indications Facioscapulohumeral muscular dystrophy; Limb girdle muscular dystrophies
Focus Adverse reactions; Pharmacodynamics
Sponsors aTyr Pharma

25 Apr 2017 According to an aTyr Pharma media release, results from this trial were presented at the American Academy of Neurology (AAN) Annual Meeting 2017.
24 Apr 2017 According to an aTyr Pharma media release, results from this trial will be presented at the upcoming American Academy of Neurology (AAN) 69th Annual Meeting.
18 Jan 2017 Results published in the aTyr Pharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com